BioSpace News Archive

The Fact MR survey on behavioral health treatment market offers detailed analysis on the key growth drivers and trends affecting demand in the market.

Amgen announced that the U.S. Food and Drug Administration has accepted a Biologics License Application and granted Priority Review for tezepelumab in the treatment of asthma.

The demand within the global urinary tract infection treatment market is expected to grow alongside advancements in medical diagnosis.

Sparx Therapeutics announced a plan to build a 1,200,000-square-foot manufacturing facility in Yangzhou, China, inching closer to becoming a commercial stage biopharma.

Tensor Surgical, Inc. is pleased to announce the appointment of Justin C. Anderson (Henderson, NV) as the CEO and President, and a member of the Board of Directors.

AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA).

Hyperfine today announced their entry into a definitive business combination agreement with HealthCor Catalio Acquisition Corp.

The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel Topline results are expected during the fourth quarter of 2021

Generation Bio Co. announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET.

Trevena, Inc. today announced the Company’s partner in China has enrolled the first patient in a Phase 3 trial for OLINVYK (oliceridine) injection, a novel IV analgesic approved in the U.S. by the Food and Drug Administration (FDA) for acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.